The 60-second version of Sigachi Industries Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
Nothing stands out as clearly improving on the years of data available.
No clear supporting case emerges from the available numbers.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹302 Cr | ₹399 Cr | ₹488 Cr | ₹478 Cr | +16.5% |
| EBITDA | ₹65 Cr | ₹86 Cr | ₹119 Cr | ₹61 Cr | -1.9% |
| EBITDA Margin | 21.4% | 21.6% | 24.4% | 12.8% | — |
| PAT (Net Profit) | ₹44 Cr | ₹57 Cr | ₹70 Cr | -₹82 Cr | — |
| EPS | ₹1.42 | ₹1.54 | ₹2.06 | ₹-2.14 | — |
| ROE | 16.2% | 13.3% | 11.6% | -15.7% | — |
| ROCE | 19.2% | 14.8% | 15.6% | -13.1% | — |
| Total Debt | ₹68 Cr | ₹151 Cr | ₹142 Cr | ₹162 Cr | +33.3% |
| Free Cash Flow | -₹72 Cr | -₹72 Cr | -₹16 Cr | -₹88 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| CIPLA LTD | 31.8x | 9.8% |
| DIVI S LABORATORIES LTD | 83.0x | 17.5% |
A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you. 6 high-severity red flags sit above this conclusion and should be read first.